Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Carlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue Estimates
Carlsmed, Inc. (CARL) delivered earnings and revenue surprises of +2.50% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -26.09% and -9.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Will Carlsmed, Inc. (CARL) Report Negative Earnings Next Week? What You Should Know
Carlsmed, Inc. (CARL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Wall Street Analysts See a 51.94% Upside in Carlsmed, Inc. (CARL): Can the Stock Really Move This High?
The consensus price target hints at a 51.9% upside potential for Carlsmed, Inc. (CARL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
Here is how Align Technology (ALGN) and Carlsmed, Inc. (CARL) have performed compared to their sector so far this year.
Zacks
Wall Street Analysts Think Carlsmed, Inc. (CARL) Could Surge 90.77%: Read This Before Placing a Bet
The mean of analysts' price targets for Carlsmed, Inc. (CARL) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
BTIG Research Reiterates Buy Rating for Carlsmed (NASDAQ:CARL)
BTIG Research reiterated a 'buy' rating and set a $23.00 price target on shares of Carlsmed in a research note on Wednesday...
MarketBeat
Carlsmed Q1 Earnings Call Highlights
Carlsmed (NASDAQ:CARL) reported first-quarter 2026 revenue of $16.1 million, up 58% from $10.2 million in the prior-year period, as the company highlighted continued surgeon adoption of its...
MarketBeat
Carlsmed, Inc. (CARL) Reports Q1 Loss, Tops Revenue Estimates
Carlsmed, Inc. (CARL) delivered earnings and revenue surprises of +24.71% and +12.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.